

ITEMS RECOMMENDED BETWEEN ORDINARY MEETINGS (MARCH 2021 - JULY 2021)

SPONSOR, TYPE OF SUBMISSION	DRUG TYPE AND USE	LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION	PBAC OUTCOME	
<p>ADRENALINE</p> <p>I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector</p> <p>I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector</p> <p>Adrenaline Jr Mylan® Anapen Junior 150® Epipen Jr® Adrenaline Mylan® Epipen® Anapen 300® Anapen 500®</p> <p>Alphapharm Pty Ltd Arrotex Pharmaceuticals Pty Ltd</p> <p>Other Business (Change to listing)</p>	<p>Acute allergic reaction with anaphylaxis</p>	<p>To seek PBAC confirmation on changing the maximum quantities of adrenaline autoinjectors from one to two and updating the administrative note such that no increase in quantity is allowed.</p>	<p>Recommended</p>	<p>The PBAC recommended an increase to the maximum quantities of adrenaline autoinjectors, from one to two. The PBAC also recommended the removal of the administrative note regarding increases to maximum quantity</p>